clinical trials

News

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

Novo, Lilly trade oral GLP-1 data readouts at ECO

Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.

News

e-Lung software in the clinical setting, by Brainomix

Boehringer, Brainomix plan new trial of lung fibrosis AI

Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

AZ cues up broader use of Imfinzi in bladder cancer

Readout for AZ's hypoparathyroidism drug raises questions

Novo, Lilly trade oral GLP-1 data readouts at ECO

Boehringer, Brainomix plan new trial of lung fibrosis AI

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks